Australian Gonococcal Surveillance Programme
1 July to 30 September 2019
Monica M Lahra and Tiffany R Hogan
Communicable Diseases Intelligence
ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2020 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-Non-Commercial-NoDerivatives 4.0 International Licence from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

Restrictions
The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

- the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.itsanhonour.gov.au);
- any logos (including the Department of Health’s logo) and trademarks;
- any photographs and images;
- any signatures; and
- any material belonging to third parties.

Disclaimer
Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

Enquiries
Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

Communicable Diseases Network Australia
Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. http://www.health.gov.au/cdna

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

Editor
Tanja Farmer

Deputy Editor
Simon Petrie

Design and Production
Kasra Yousefi

Editorial Advisory Board
David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

Website
http://www.health.gov.au/cdi

Contacts
Communicable Diseases Intelligence is produced by: Health Protection Policy Branch Office of Health Protection Australian Government Department of Health GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Email:
cdi.editor@health.gov.au

Submit an Article
You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: http://health.gov.au/cdi.

Further enquiries should be directed to:
cdi.editor@health.gov.au.
Quarterly report

Australian Gonococcal Surveillance Programme

1 July to 30 September 2019

Monica M Lahra and Tiffany R Hogan

Introduction

The National Neisseria Network (NNN), Australia, comprises reference laboratories in each state and territory that report data on susceptibility profiles for clinical *Neisseria gonorrhoeae* isolates from each jurisdiction for an agreed group of antimicrobial agents, for the Australian Gonococcal Surveillance Programme (AGSP). The antibiotics are ceftriaxone, azithromycin, ciprofloxacin and penicillin; they represent current or potential agents used for the treatment of gonorrhoea. Ceftriaxone combined with azithromycin is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns in Australia, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

Results

A summary of the proportion of isolates with decreased susceptibility to ceftriaxone (minimum inhibitory concentration, MIC 0.06–0.25 mg/L), and the proportion resistant to azithromycin (MIC ≥ 1.0 mg/L), ciprofloxacin (MIC ≥ 1.0 mg/L), and penicillin (MIC ≥ 1.0 mg/L) for Quarter 3 2019 is shown in Table 1.

Ceftriaxone

For the AGSP, the category of ceftriaxone decreased susceptibility (DS) includes the MIC values 0.06–0.25 mg/L, and the proportion resistant to azithromycin (MIC ≥ 1.0 mg/L), ciprofloxacin (MIC ≥ 1.0 mg/L), and penicillin (MIC ≥ 1.0 mg/L) for Quarter 3 2019 is shown in Table 1.

In the third quarter of 2019, the proportion of isolates with ceftriaxone decreased susceptibility (MIC values 0.06–0.25 mg/L) in Australia was 1.3%, slightly lower than the first quarter (1.9%) of 2019. The mean percentage of the year to date data indicates an overall decline in the rate of decreased susceptibility in 2019 compared to that of 2018 (Table 2). In the third quarter of 2019, New South Wales, South Australia and Victoria each have reported one isolate with a ceftriaxone MIC value greater than 0.125 mg/L. Of note, there was one isolate from Victoria that exhibited DS to ceftriaxone (MIC = 0.06 mg/L) and resistance to azithromycin, ciprofloxacin, and penicillin. All other isolates with decreased susceptibility to ceftriaxone recorded in Table 3 were susceptible to azithromycin (Table 3).

The national trend of strains with ceftriaxone decreased susceptibility (MIC 0.06 and ≥ 0.125 mg/L) since 2010 is shown in Table 2.

A summary of ceftriaxone DS strains that were penicillin and ciprofloxacin resistant, or isolated from extragenital sites (rectal and pharyngeal) for Quarter 3, 2019 by state or territory, and by sex is shown in Table 3.
Azithromycin

In the third quarter of 2019, the percentage of isolates with resistance to azithromycin (MIC ≥ 1.0 mg/L) has declined over each quarter of 2019 and is lower than the proportion (6.3%) resistant to azithromycin in 2018. Whilst the national data from the 2019 year to date demonstrate approximately double the rate of resistance to azithromycin compared with 2013–2015 data (2.1–2.6%),¹ a trend towards declining resistance since 2017 in Australia has been observed, despite reports of increasing azithromycin resistance in Neisseria gonorrhoeae worldwide.²

In quarter 3 2019, all Australian states and territories reported isolates with resistance to azithromycin, except for remote areas of the Northern Territory. Compared with the previous quarter of 2019, the states and territories reporting an increase in the number and proportion of N. gonorrhoeae isolates with resistance to azithromycin were Queensland, Tasmania, Victoria and Western Australia (the latter showing a significant rise in its urban area). There was one isolate from Victoria that exhibited resistance to azithromycin, decreased susceptibility to ceftriaxone (MIC = 0.064 mg/L), and resistance to both ciprofloxacin and penicillin.

Notably, four isolates in this quarter have demonstrated high-level resistance to azithromycin (MIC ≥ 256 mg/L), and they were found in four different states: New South Wales, Queensland, Tasmania, and metropolitan Western Australia. In addition, six strains from Victoria, three strains in New South Wales, one strain from Queensland and another from South Australia, isolated from extragenital sites, showed decreased susceptibility to ceftriaxone. The national trend of azithromycin resistance in isolates since 2012 is shown in Table 4.

Dual therapy using ceftriaxone plus azithromycin is the recommended treatment for gonorrhoea as a strategy to temper development of more widespread ceftriaxone resistance. Patients with infections in extragenital sites, where the isolate has decreased susceptibility to ceftriaxone, should have a test of cure cultures collected. Continued surveillance to monitor N. gonorrhoeae with elevated MIC values, coupled with sentinel site surveillance in high-risk populations, remains essential to inform therapeutic strategies, to identify incursion of resistant strains, and to detect instances of treatment failure.

Author details

Monica M Lahra¹
Tiffany R Hogan¹

1. The World Health Organisation Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, New South Wales Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031

Corresponding author

Professor Monica M Lahra

World Health Organization Collaborating Centre for STI and AMR, Sydney, and Neisseria Reference Laboratory, Microbiology Department, SEALS, The Prince of Wales Hospital, Randwick, NSW, 2031. School of Medical Sciences, Faculty of Medicine, the University of New South Wales, NSW 2050 Australia.

Telephone: +61 2 9382 9050.
Facsimile: +61 2 9382 9210.
Email: monica.lahra@health.nsw.gov.au

References

1. Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme. Annual Report 2017. Commun Dis Intell (2018). 2018;42. pii: S2209-5081(18)00013-1.

2. Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364.
Table 1: Gonococcal isolates showing decreased susceptibility to ceftriaxone, and resistance to azithromycin, ciprofloxacin and penicillin, Australia, 1 July to 30 September 2019, by state or territory

| State or territory                  | Number of isolates tested | Decreased susceptibility | Resistance |
|-------------------------------------|---------------------------|---------------------------|------------|
|                                     | Q3, 2019                  | Ceftriaxone | Azithromycin | Penicillin* | Ciprofloxacin |
|                                     | n | %      | n | %      | n | %      | n | %      |
| Australian Capital Territory        | 43 | 0.0 | 2 | 4.7 | 9 | 20.9 |
| New South Wales                     | 892 | 0.7 | 38 | 4.3 | 253 | 28.4 | 264 | 29.6 |
| Queensland                          | 451 | 0.7 | 9 | 2.0 | 100 | 22.2 | 87 | 19.3 |
| South Australia                     | 133 | 1.5 | 1 | 0.8 | 21 | 15.8 | 27 | 20.3 |
| Tasmania                            | 16 | 0.0 | 1 | 6.3 | 7 | 43.8 | 5 | 31.3 |
| Victoria                            | 715 | 2.2 | 41 | 5.7 | 139 | 19.4 | 201 | 28.1 |
| Northern Territory urban & rural   | 18 | 0.0 | 1 | 5.6 | 3 | 16.7 | 3 | 16.7 |
| Northern Territory remote           | 14 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Western Australia urban & rural    | 176 | 1.7 | 6 | 3.4 | 44 | 25.0 | 53 | 30.1 |
| Western Australia remote            | 19 | 5.3 | 1 | 5.3 | 2 | 10.5 | 1 | 5.3 |
| **Australia**                       | **2477** | **1.3** | **100** | **4.0** | **571** | **23.1** | **650** | **26.2** |

*Penicillin resistance includes MIC value of ≥ 1.0 mg/L, or penicillinase production.
Table 2: Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone at MIC values of 0.06 mg/L, ≥ 0.125 mg/L, and total percentage, Australia, 2011 to 2017, 1 January to 31 March 2019, 1 April to 30 June 2019, and 1 July to 30 September 2019

| Ceftriaxone MIC mg/L | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 Q1 | 2019 Q2 | 2029 Q3 |
|----------------------|------|------|------|------|------|------|------|------|------|---------|---------|---------|
| 0.06                 | 4.8% | 3.2% | 4.1% | 8.2% | 4.8% | 1.7% | 1.7% | 1.0% | 1.7% | 1.8%    | 0.7%    | 1.1%    |
| ≥ 0.125              | 0.1% | 0.1% | 0.3% | 0.6% | 0.6% | 0.1% | 0.1% | 0.0% | 0.1% | 0.1%    | 0.1%    | 0.1%    |
| Total                | 4.9% | 3.3% | 4.4% | 8.8% | 5.4% | 1.8% | 1.7% | 1.1% | 1.7% | 1.9%    | 0.8%    | 1.3%    |
Table 3 Percentage of gonococcal isolates with decreased susceptibility to ceftriaxone (MIC ≥ 0.06 mg/L) and that were penicillin (Pen) and ciprofloxacin (Cip) resistant (R), isolated from extragenital sites, and by sex, Australia, 1 July to 30 September 2019

| State or territory                  | Total | Pen R + Cip R | Males | Females | Extragenital sites |
|-------------------------------------|-------|---------------|-------|---------|-------------------|
|                                     |       | n  | %    | n  | %    | n  | %    | n  | %    |
| Australian Capital Territory        | 0     | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  |
| New South Wales                     | 6     | 5  | 83.3 | 5  | 83.3 | 1  | 16.7 | 3  | 50.0 |
| Queensland                          | 3     | 0  | 0.0  | 3  | 100.0| 0  | 0.0  | 1  | 33.3 |
| South Australia                     | 2     | 1  | 50.0 | 2  | 100.0| 0  | 0.0  | 1  | 50.0 |
| Tasmania                            | 0     | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  |
| Victoria                            | 16    | 10 | 62.5 | 11 | 68.8 | 4  | 25.0 | 6  | 37.5 |
| Northern Territory urban & rural   | 0     | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  |
| Northern Territory remote           | 0     | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  | 0  | 0.0  |
| Western Australia urban & rural    | 3     | 2  | 66.7 | 2  | 66.7 | 1  | 33.3 | 0  | 0.0  |
| Western Australia remote            | 1     | 1  | 100.0| 1  | 100.0| 0  | 0.0  | 0  | 0.0  |
| **Australia**                       | **31**| **19**| **61.3**| **24**| **77.4**| **6**| **19.4**| **11**| **35.5** |
Table 4: Percentage of gonococcal isolates with resistance to azithromycin (MIC ≥ 1.0 mg/L), Australia, 2012 to 2018, 1 January to 31 March 2019, 1 April to 30 June 2019, and 1 July to 30 September 2019

| Azithromycin resistance | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 Q1 | 2019 Q2 | 2019 Q3 |
|-------------------------|------|------|------|------|------|------|------|---------|---------|---------|
| MIC ≥ 1mg/L             | 1.3% | 2.1% | 2.5% | 2.6% | 5.0% | 9.3% | 6.3% | 5.9%    | 5.1%    | 4.1%    |